Shuttle Pharmaceuticals Files S-1/A Amendment
Ticker: SHPH · Form: S-1/A · Filed: Mar 5, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | S-1/A |
| Filed Date | Mar 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, pharmaceuticals, ipo
TL;DR
Shuttle Pharma filed an S-1/A, looks like they're still aiming for an IPO.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an S-1/A amendment on March 5, 2025, for its registration statement. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Gaithersburg, MD. Anatoly Dritschilo, M.D. is the Chief Executive Officer.
Why It Matters
This filing indicates Shuttle Pharmaceuticals is moving forward with its public offering process, which could provide capital for drug development and expansion.
Risk Assessment
Risk Level: medium — As a pharmaceutical company in the registration process, it faces typical risks associated with drug development, regulatory approval, and market acceptance.
Key Numbers
- 333-284889 — SEC File Number (Identifies the specific registration filing with the SEC.)
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- March 5, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- 2834 (industry_code) — Standard Industrial Classification
- Gaithersburg, MD (location) — Principal Executive Office
- Anatoly Dritschilo, M.D. (person) — Chief Executive Officer
- 333-284889 (registration_number) — SEC File Number
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a registration statement (Form S-1) filed with the SEC, indicating updates or changes to the initial filing for a public offering.
When was this amendment filed?
The amendment was filed on March 5, 2025.
What industry is Shuttle Pharmaceuticals Holdings, Inc. in?
The company is in the Pharmaceutical Preparations industry, with a Standard Industrial Classification code of 2834.
Who is the Chief Executive Officer of Shuttle Pharmaceuticals Holdings, Inc.?
Anatoly Dritschilo, M.D. is the Chief Executive Officer.
Where is Shuttle Pharmaceuticals Holdings, Inc. located?
The company's principal executive office is located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on March 5, 2025 by Anatoly Dritschilo, M.D. regarding Shuttle Pharmaceuticals Holdings, Inc. (SHPH).